Stockreport

Neurocrine: A Buy Amid CNS Pipeline Growth And Ingrezza's Strength (Rating Upgrade) [Seeking Alpha]

Neurocrine Biosciences, Inc.  (NBIX) 
Last neurocrine biosciences, inc. earnings: 2/4 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: neurocrine.com/about-us/webcasts-presentations
PDF Play 8min Summary Neurocrine Biosciences' Ingrezza has grown into a multibillion-dollar drug, but the company's stock has underperformed the S&P 500 since 2019. [Read more]